Mumbai: Eris Lifesciences has tied up with Hyderabad-based Natco Pharma to commercialise semaglutide, forward of the blockbuster weight-loss drug’s patent expiry.
The partnership comes on the heels of Natco receiving regulatory approval from the Central Medication Customary Management Organisation (CDSCO) on 14 February to fabricate generic semaglutide for the Indian market. This paves the best way for a launch anticipated in March 2026, Eris stated in an announcement on Tuesday.
The collaboration will leverage Eris’s industrial presence within the diabetes section and Natco’s manufacturing and regulatory prowess in complicated formulations, the corporate stated.
The product will goal sort 2 diabetes administration, aligning with unmet wants in India’s increasing metabolic care panorama.
Eris has a robust presence in diabetology with a large specialist attain. In 2024, it signed a long-term take care of Biocon to amass its home branded formulations enterprise, together with its insulin merchandise.
“Semaglutide represents one of the vital therapeutic advances in metabolic care in recent times…With our robust industrial infrastructure and deep engagement in persistent therapies, we consider Eris is well-positioned to drive speedy adoption and improve affected person entry in India,” stated chairman and managing director Amit Bakshi.
He additional added that Eris has been proactively getting ready its industrial technique to take part within the GLP-1 alternative.
Mint reported earlier that offers and partnerships to commercialise semaglutide could be on the rise forward of the drug’s patent expiry as firms with totally different strengths be a part of fingers to realize floor in a extremely aggressive market.
Earlier this month, OneSource Pharma introduced a partnership with Hikma to commercialise generic semaglutide in Saudi Arabia.
In December, Ajanta Pharma introduced a take care of Biocon to commercialise the drug in a number of African and Asian markets. Ajanta is scouting for an additional associate in India. Dr Reddy’s has a partnership with OneSource introduced final yr, and is planning to provide to different home companions too, its management stated in the course of the firm’s Q3FY26 press convention in January.
Cipla and Emcure have introduced distribution offers with innovators Eli Lilly and Novo Nordisk, respectively.
The deal frenzy comes on the heels of fast-expanding demand for weight-loss medicine like semaglutide in India. GLP-1 drug gross sales have already crossed ₹1,000 crore in lower than a yr of launches. At the moment, innovator medicine Mounjaro, Wegovy and Ozempic dominate, however the entry of generic variations of semaglutide, priced cheaply, is predicted to additional broaden the market.
Novo Nordisk is ready to lose patent exclusivity for semaglutide in India in March 2026.